X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2076) 2076
Newspaper Article (80) 80
Magazine Article (35) 35
Newsletter (35) 35
Book Chapter (13) 13
Dissertation (4) 4
Book / eBook (1) 1
Conference Proceeding (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
emtricitabine (1689) 1689
humans (1516) 1516
science & technology (1406) 1406
life sciences & biomedicine (1270) 1270
tenofovir (1209) 1209
male (858) 858
hiv infections - drug therapy (844) 844
deoxycytidine - analogs & derivatives (834) 834
female (807) 807
infectious diseases (760) 760
adult (722) 722
adenine - analogs & derivatives (713) 713
hiv (666) 666
human immunodeficiency virus--hiv (624) 624
anti-hiv agents - therapeutic use (609) 609
anti-hiv agents - administration & dosage (498) 498
middle aged (478) 478
deoxycytidine - therapeutic use (466) 466
hiv infections - prevention & control (456) 456
immunology (427) 427
adenine - therapeutic use (397) 397
drug combinations (392) 392
hiv infection (389) 389
deoxycytidine - administration & dosage (384) 384
aids/hiv (383) 383
drug therapy (374) 374
pharmacology & pharmacy (367) 367
adenine - administration & dosage (348) 348
antiretroviral drugs (341) 341
organophosphonates - therapeutic use (341) 341
drug therapy, combination (328) 328
antiviral agents (321) 321
treatment outcome (311) 311
organophosphonates - administration & dosage (306) 306
virology (290) 290
antiretroviral therapy (277) 277
hiv infections - virology (273) 273
hiv-1 - drug effects (265) 265
lamivudine (264) 264
anti-hiv agents - adverse effects (262) 262
health aspects (255) 255
viral load (246) 246
prevention (231) 231
microbiology (228) 228
acquired immune deficiency syndrome--aids (225) 225
young adult (222) 222
infections (221) 221
pre-exposure prophylaxis (213) 213
efavirenz (211) 211
clinical trials (206) 206
research (205) 205
emtricitabine - therapeutic use (200) 200
highly active antiretroviral therapy (196) 196
tenofovir - therapeutic use (192) 192
hiv-1 (185) 185
antiretroviral agents (184) 184
deoxycytidine - adverse effects (182) 182
dosage and administration (176) 176
prophylaxis (176) 176
analysis (173) 173
cd4 lymphocyte count (173) 173
adenine - adverse effects (166) 166
lamivudine - therapeutic use (164) 164
abridged index medicus (162) 162
emtricitabine - administration & dosage (158) 158
reverse transcriptase inhibitors - therapeutic use (154) 154
organophosphonates - adverse effects (150) 150
virus diseases (149) 149
adolescent (148) 148
drug resistance (148) 148
aids (147) 147
tenofovir - administration & dosage (143) 143
human immunodeficiency virus (140) 140
drug resistance, viral (138) 138
drugs (138) 138
general & internal medicine (136) 136
medicine, general & internal (136) 136
anti-hiv agents - pharmacology (133) 133
medicine (133) 133
risk factors (130) 130
patients (127) 127
anti-hiv agents - pharmacokinetics (124) 124
hiv-1 - genetics (122) 122
aged (120) 120
animals (120) 120
medication adherence (120) 120
mutation (120) 120
viruses (120) 120
emtricitabine, tenofovir disoproxil fumarate drug combination (119) 119
research article (118) 118
care and treatment (117) 117
drug administration schedule (115) 115
pre-exposure prophylaxis - methods (114) 114
pharmacology (113) 113
science & technology - other topics (113) 113
multidisciplinary sciences (111) 111
hiv infections - complications (110) 110
antiretroviral therapy, highly active (109) 109
deoxycytidine - pharmacology (109) 109
hiv infections - epidemiology (108) 108
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2172) 2172
German (27) 27
Spanish (26) 26
French (16) 16
Japanese (6) 6
Italian (4) 4
Portuguese (4) 4
Chinese (2) 2
Dutch (2) 2
Danish (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 12/2015, Volume 373, Issue 23, pp. 2237 - 2246
Journal Article
Journal of controlled release, ISSN 0168-3659, 09/2018, Volume 286, pp. 315 - 325
Journal Article
PloS one, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, pp. e0134430 - e0134430
Objective To assess, in a clinical cohort, the efficacy of switching treatment in virologically-suppressed patients to tenofovir/emtricitabine/rilpivirine as a... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Tenofovir - blood | Follow-Up Studies | Humans | Middle Aged | Emtricitabine, Rilpivirine, Tenofovir Drug Combination - therapeutic use | Male | Tenofovir - administration & dosage | Anti-HIV Agents - administration & dosage | Rilpivirine - therapeutic use | Rilpivirine - blood | Adult | Anti-HIV Agents - therapeutic use | Female | Anti-HIV Agents - blood | Drug Therapy, Combination | Rilpivirine - administration & dosage | Emtricitabine - administration & dosage | Emtricitabine - therapeutic use | Tenofovir - therapeutic use | Emtricitabine, Rilpivirine, Tenofovir Drug Combination - administration & dosage | Emtricitabine - blood | HIV Infections - drug therapy | Drug Substitution | Viral Load - drug effects | Drug Combinations | Virus diseases | Highly active antiretroviral therapy | Care and treatment | Protease inhibitors | Proteases | DNA polymerases | Health aspects | Emtricitabine | Antiretroviral drugs | RNA-directed DNA polymerase | Viremia | Viruses | Proteinase inhibitors | Signal monitoring | Patients | Switching | Chromatography | Antiretroviral therapy | Tenofovir | Non-nucleoside reverse transcriptase inhibitors | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Human immunodeficiency virus--HIV | Scientific imaging | Drug therapy | Mass spectrometry | Drug dosages | Genotypes | Index Medicus | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
PloS one, ISSN 1932-6203, 11/2016, Volume 11, Issue 11, pp. e0165505 - e0165505
The coformulation of the nucleos(t) ide analogs (NA) tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC) is approved for HIV-infection treatment... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Anti-HIV Agents - pharmacology | Deoxyadenine Nucleotides - metabolism | Tenofovir - blood | Diphosphates - metabolism | Prospective Studies | Humans | Middle Aged | Tenofovir - pharmacology | Male | Emtricitabine - pharmacology | HIV - drug effects | Young Adult | Emtricitabine - pharmacokinetics | Computer Simulation | Tenofovir - metabolism | Adult | Female | Deoxycytosine Nucleotides - metabolism | Anti-HIV Agents - blood | Anti-HIV Agents - metabolism | Emtricitabine - metabolism | Emtricitabine - blood | Tenofovir - pharmacokinetics | Polyphosphates - metabolism | Models, Biological | Anti-HIV Agents - pharmacokinetics | HIV Infections - drug therapy | DNA polymerases | Antiviral agents | Models | Health aspects | Analysis | Plasma | RNA-directed DNA polymerase | Prophylaxis | Leukocytes (mononuclear) | Infections | Dosage | Tenofovir | Analogs | Acquired immune deficiency syndrome--AIDS | Metabolites | Human immunodeficiency virus--HIV | Peripheral blood mononuclear cells | Drug dosages | Pharmaceutical sciences | Emtricitabine | Antiretroviral drugs | Pharmacodynamics | Computer simulation | Nonlinear analysis | Data processing | Pharmacology | Metabolism | Deoxyadenosine | Simulation | Pharmacy | Intracellular | Pharmacokinetics | Index Medicus | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
AIDS care, ISSN 1360-0451, 10/2015, Volume 28, Issue 3, pp. 401 - 408
This 96-week, randomized, open-label study was designed to assess the efficacy and safety of two single-tablet regimens in treatment naïve HIV-1-infected... 
treatment-naive | single-tablet regimen | Antiretroviral therapy | efavirenz | rilpivirine | singletablet regimen | treatmentnaive | Psychology, Multidisciplinary | Social Sciences | Life Sciences & Biomedicine | Psychology | Social Sciences, Biomedical | Respiratory System | Health Care Sciences & Services | Public, Environmental & Occupational Health | Health Policy & Services | Biomedical Social Sciences | Science & Technology | Medication Adherence - statistics & numerical data | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use | Tablets | Humans | Middle Aged | Self Report | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - adverse effects | Emtricitabine, Rilpivirine, Tenofovir Drug Combination - therapeutic use | HIV Infections - psychology | Male | RNA, Viral - blood | Treatment Outcome | Patient Outcome Assessment | HIV-1 - genetics | Viral Load | Emtricitabine, Rilpivirine, Tenofovir Drug Combination - adverse effects | HIV-1 - isolation & purification | Drug-Related Side Effects and Adverse Reactions | Quality of Life | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Discontinued | Drugs | Drug abuse | Transportation safety | Life assessment | Efavirenz | Adherence | Tenofovir | Intestine | Antiretroviral agents | Human immunodeficiency virus--HIV | Safety | Emtricitabine | Antiretroviral drugs | Critical incidents | Diarrhea | Efficacy | Ribonucleic acid--RNA | Adhesion | Patients | Quality of life | Selfreport | Diarrhoea | Adults | Quality assessment | Index Medicus | AIDS/HIV
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2016, Volume 3, Issue 12, pp. e561 - e568
Journal Article
Journal Article
Journal Article